Fenwick represented Federation Bio, a microbial therapeutics company targeting diseases in which the human microbiome can play a curative role, in its $50 million Series A financing. Horizons Ventures led the Series A financing, joined by existing investors Venrock and Altitude, and additional new investors Seventure Partners/Health for Life Capital.
Federation Bio will use proceeds from the financing to build out its in-house development process to enable Phase 1/2 manufacturing and advance its lead program into the clinic. More information can be obtained from Federation Bio’s announcement.
The Fenwick transaction team was led by corporate partner Matthew Rossiter and associates Alina Azizian and Myles Gutenkunst.